2023
In Vivo Verification of Electron Paramagnetic Resonance Biodosimetry Using Patients Undergoing Radiation Therapy Treatment
Draeger E, Roberts K, Decker R, Bahar N, Wilson L, Contessa J, Husain Z, Williams B, Flood A, Swartz H, Carlson D. In Vivo Verification of Electron Paramagnetic Resonance Biodosimetry Using Patients Undergoing Radiation Therapy Treatment. International Journal Of Radiation Oncology • Biology • Physics 2023, 119: 292-301. PMID: 38072322, DOI: 10.1016/j.ijrobp.2023.11.029.Peer-Reviewed Original ResearchHealthy volunteersDose rangeTotal body irradiationTotal body irradiation treatmentSignificant correlationRadiation therapy patientsPatient ageBody irradiationImmediate triageTherapy patientsClinical conditionsParticipants' teethPatientsNeck patientsUnknown dosesDosePatient dataRadiotherapy treatmentRadiation doseTeethTreatmentVolunteersSubsequent fractionsLuminescent dosimetersRadiation response
2021
Pediatric Hodgkin Lymphoma, Version 3.2021.
Flerlage J, Hiniker S, Armenian S, Benya E, Bobbey A, Chang V, Cooper S, Coulter D, Cuglievan B, Hoppe B, Isenalumhe L, Kelly K, Kersun L, Lamble A, Larrier N, Magee J, Oduro K, Pacheco M, Price A, Roberts K, Smith C, Sohani A, Trovillion E, Walling E, Xavier A, Burns J, Campbell M. Pediatric Hodgkin Lymphoma, Version 3.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 733-754. PMID: 34214968, DOI: 10.6004/jnccn.2021.0027.Peer-Reviewed Original ResearchConceptsPediatric Hodgkin lymphomaClassic Hodgkin lymphomaHodgkin's lymphomaNCCN Clinical Practice GuidelinesClinical practice guidelinesCurrent treatment regimensNCCN guidelinesRefractory settingSystemic therapyCurable formTreatment regimensPrinciples of pathologyDiagnostic evaluationLate effectsPractice guidelinesRadiation therapyTreatment efficacyLymphomaTherapyTreatmentGuidelinesRegimensWorkupCancerStaging
2019
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. Journal Of The National Comprehensive Cancer Network 2019, 17: 650-661. PMID: 31200358, DOI: 10.6004/jnccn.2019.0029.Peer-Reviewed Original ResearchMeSH KeywordsAdultAftercareAntineoplastic Agents, ImmunologicalDrug Resistance, NeoplasmHumansImmunotherapy, AdoptiveLymphoma, FollicularLymphoma, Large B-Cell, DiffuseMedical OncologyNeoplasm Recurrence, LocalNeoplasm StagingPhosphoinositide-3 Kinase InhibitorsReceptors, Chimeric AntigenSignal TransductionUnited StatesConceptsDiffuse large B-cell lymphomaB-cell lymphomaRefractory follicular lymphomaFollicular lymphomaRefractory diffuse large B-cell lymphomaCAR T-cell therapyLarge B-cell lymphomaPoor clinical outcomeT-cell therapyNovel treatment optionsNCCN guidelinesClinical outcomesHodgkin's lymphomaTreatment optionsCommon subtypeHistologic transformationB cellsLymphomaTreatmentImportant updatesPatientsTherapySubtypesTFL
2017
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.
Wierda W, Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis C, Bartlett N, Byrd J, Caimi P, Fayad L, Fisher R, Glenn M, Habermann T, Harris N, Hernandez-Ilizaliturri F, Hoppe R, Horwitz S, Kaminski M, Kelsey C, Kim Y, Krivacic S, LaCasce A, Martin M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad A, Snyder E, Sokol L, Swinnen L, Vose J, Yahalom J, Dwyer M, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. Journal Of The National Comprehensive Cancer Network 2017, 15: 293-311. PMID: 28275031, DOI: 10.6004/jnccn.2017.0030.Peer-Reviewed Original ResearchConceptsSmall lymphocytic lymphomaChronic lymphocytic leukemiaTreatment of patientsNCCN Clinical Practice GuidelinesCD20 monoclonal antibodyNCCN Guidelines InsightsClinical practice guidelinesRelapsed/refractory CLL/SLLChemoimmunotherapy regimensLymphocytic lymphomaCritical signaling pathwaysLymphocytic leukemiaSmall molecule inhibitorsCLL/SLLBcl-2 familyBcl-2Monoclonal antibodiesMolecule inhibitorsSignaling pathwayPractice guidelinesPatientsNCCNTreatmentLymphomaRegimens
2013
Evidence-Based Cardiovascular Management of Patients Receiving Radiotherapy to the Heart
Taylor B, Evans S, Roberts K. Evidence-Based Cardiovascular Management of Patients Receiving Radiotherapy to the Heart. 2013, 409-420. DOI: 10.1007/978-1-4471-4441-0_28.ChaptersCardiovascular managementLong-term outcome studiesLate cardiovascular complicationsPrimary care physiciansEffect of radiotherapyRisks of radiotherapyCardiovascular complicationsCardiotoxic chemotherapyCare physiciansCardiovascular functionOutcome studiesCardiovascular teamRT planningRadiotherapyCardiovascular systemPatientsCancer therapyTherapy techniquesCell populationsAdverse changesChemotherapyHeartAdditive effectRiskTreatment
2004
Relation of clinical success in coronary brachytherapy to dose
Singh HS, Yue N, Azimi N, Nath R, Roberts KB, Pfau S. Relation of clinical success in coronary brachytherapy to dose. The American Journal Of Cardiology 2004, 94: 847-852. PMID: 15464663, DOI: 10.1016/j.amjcard.2004.06.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyCase-Control StudiesConnecticutCoronary AngiographyCoronary RestenosisCoronary VesselsDose-Response Relationship, RadiationFemaleFollow-Up StudiesHumansMaleMiddle AgedMultivariate AnalysisRadiotherapy DosageRetrospective StudiesStatistics as TopicTreatment OutcomeUltrasonography, InterventionalConceptsTreatment failureExternal elastic membraneTreatment successStent restenosisIntravascular ultrasoundAdequate dose deliveryRecurrent restenosisLesion patternsPrimary treatmentCoronary brachytherapyClinical successPatientsDose prescriptionRadiation delivery systemsArteryRestenosisGyDoseBrachytherapyDose thresholdRadiation delivery devicePotential causesDose deliveryIntravascular brachytherapyTreatment